Analysis shows lower BMI is linked to poorer prognosis in patients with metastatic breast cancer treated with CDK4/6 inhibitors, suggesting a need for tailored therapies.
In HR positive advanced breast cancer patients treated with first-line CDK4/6 inhibitors, lower BMI is associated with poorer prognosis.
No takes yet. Share an insight, caveat, or question.
Tao Sun (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: